Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Jnit: NT\$ thousand			
Accounting Title	2017/09/30	2016/12/31	2016/09/30
Balance Sheet			
Current assets			
Total cash and cash equivalents	353,598	309,771	306,554
Total Current investments in debt instrument without active market	285,160	455,399	518,94
Accounts receivable, net	62,491	23,328	12,04
Accounts receivable due from related parties, net	0	24,472	6,49
Other receivables, net	4,907	2,838	13,05
Total current tax assets	2,120	1,907	1,79
Total inventories	53,530	50,395	38,62
Total prepayments	29,397	19,989	41,79
Total other current assets	6,098	48,402	18,36
Total current assets	797,301	936,501	957,65
Non-current assets			
Non-current financial assets at cost, net	87,000	20,000	20,00
Total Non-current investments in debt instrument without active market	0	30,000	30,00
Total property, plant and equipment	363,043	315,000	293,35
Total intangible assets	1,960	2,342	2,37
Deferred tax assets	38,876	39,599	39,10
Total other non-current assets	39,222	45,906	51,42
Total non-current assets	530,101	452,847	436,26
Total assets	1,327,402	1,389,348	1,393,91
Current liabilities			
Total accounts payable	13,788	22,069	13,82
Total other payables	45,058	42,658	36,90
Other payables to related parties	0	6	
Total other current liabilities	10,344	5,728	8,25
Total current liabilities	69,190	70,461	58,97
Non-current liabilities			
Total deferred tax liabilities	0	473	
Total other non-current liabilities	2,225	2,271	1,69
Total non-current liabilities	2,225	2,744	1,69
Total liabilities	71,415	73,205	60,67
Share capital			
Ordinary share	1,121,180	1,120,005	1,119,38
Advance receipts for share capital	0	807	1,07
Total share capital	1,121,180	1,120,812	1,120,46
Capital surplus			
Total capital surplus, additional paid-in capital	266,102	621,104	620,23
Capital surplus, treasury share transactions	2,812	2,812	2,81
Capital surplus, employee share options	27,045	15,695	10,94
Total capital surplus	295,959	639,611	633,99
Retained earnings			
Total unappropriated retained earnings (accumulated deficit)	-73,541	-356,669	-333,60
Total retained earnings	-73,541	-356,669	-333,60
Other equity interest			
Total other equity, others	0	0	
Total other equity interest	0	0	
Treasury shares	-87,611	-87,611	-87,61
Equity attributable to former owner of business combination under common control	0	0	*
Equity attributable to non-controlling interest before business combination under common control	0	0	
Total equity	1,255,987	1,316,143	1,333,24
Total liabilities and equity	1,327,402	1,389,348	1,393,91
Number of share capital awaiting retirement	0	0	
Equivalent issue shares of advance receipts for ordinary share	0	44,000	62,00
Number of shares in entity held by entity and by its subsidiaries	2,200,000	2,200,000	2,200,00

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Offic. N Ty thousand				
Accounting Title	2017/3rd	2016/3rd	2017/01/01To2017/09/30	2016/01/01To2016/09/30
Income Statement	<u>.</u>			
Total operating revenue	126,340	87,216	225,598	127,245
Total operating costs	48,376	45,319	133,204	115,327
Gross profit (loss) from operations	77,964	41,897	92,394	11,918
Gross profit (loss) from operations	77,964	41,897	92,394	11,918
Operating expenses				
Total selling expenses	6,587	2,231	13,639	6,691
Total administrative expenses	12,193	7,407	33,711	22,218
Total research and development expenses	40,393	63,429	125,435	152,415
Total operating expenses	59,173	73,067	172,785	181,324
Net operating income (loss)	18,791	-31,170	-80,391	-169,406
Non-operating income and expenses				
Total other income	4,285	12,559	18,114	40,605
Other gains and losses, net	-1,024	-4,665	-11,015	-6,843
Total non-operating income and expenses	3,261	7,894	7,099	33,762
Profit (loss) from continuing operations before tax	22,052	-23,276	-73,292	-135,644
Total tax expense (income)	-57	69	249	268
Profit (loss) from continuing operations	22,109	-23,345	-73,541	-135,912
Profit (loss)	22,109	-23,345	-73,541	-135,912
Total comprehensive income	22,109	-23,345	-73,541	-135,912
Basic earnings per share				
Total basic earnings per share	0.20	-0.21	-0.67	-1.24
Diluted earnings per share				
Total diluted earnings per share	0.20	0.00	0.00	0.00

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Unit: NT\$ thousand		
Accounting Title	2017/01/01To2017/09/30	2016/01/01To2016/09/30
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-73,292	-135,644
Profit (loss) before tax	-73,292	-135,644
Depreciation expense	44,889	29,435
Amortization expense	753	743
Provision (reversal of provision) for bad debt expense	3,504	0
Interest income	-3,680	-6,235
Share-based payments	11,971	9,530
Loss (gain) on disposal of property, plan and equipment	-99	149
Impairment loss on non-financial assets	966	592
Other adjustments to reconcile profit (loss)	0	0
Total adjustments to reconcile profit (loss)	58,304	34,214
Decrease (increase) in notes receivable	40.007	71
Decrease (increase) in accounts receivable	-42,667 24,472	6,525
Decrease (increase) in accounts receivable due from related parties  Decrease (increase) in other receivable	24,472	-6,495 -10,446
Decrease (increase) in inventories	-2,160 -4,101	-16,588
Decrease (increase) in prepayments	-9,408	-20,214
Decrease (increase) in other current assets	-272	-329
Total changes in operating assets	-34,136	-47,476
Increase (decrease) in accounts payable	-8,281	-5,796
Increase (decrease) in accounts payable to related parties	0,201	-40
Increase (decrease) in other payable	3,245	1,090
Increase (decrease) in other payable to related parties	-6	0
Increase (decrease) in other current liabilities	4,616	-3,367
Increase (decrease) in net defined benefit liability	-46	-39
Total changes in operating liabilities	-472	-8,152
Total changes in operating assets and liabilities	-34,608	-55,628
Total adjustments	23,696	-21,414
Cash inflow (outflow) generated from operations	-49,596	-157,058
Income taxes refund (paid)	-212	2,245
Net cash flows from (used in) operating activities	-49,808	-154,813
Cash flows from (used in) investing activities	100 100	
Acquisition of investments in debt instrument without active market	-190,487	-250,517
Proceeds from disposal of investments in debt instrument without active market	390,726	591,444
Acquisition of financial assets at cost	-67,000 46,604	-20,000
Acquisition of property, plant and equipment  Proceeds from disposal of property, plant and equipment	-46,604 114	-117,286
Increase in refundable deposits	-420	439
Acquisition of intangible assets	-371	-2,036
Increase in other financial assets	-5,107	-21,301
Decrease in other financial assets	47,683	12,593
Increase in prepayments for business facilities	-30,964	-49,516
Increase in other prepayments	-9,120	0
Interest received	3,771	6,519
Net cash flows from (used in) investing activities	92,221	150,339
Cash flows from (used in) financing activities	·	,
Exercise of employee share options	1,414	5,409
Net cash flows from (used in) financing activities	1,414	5,409
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	43,827	935
Cash and cash equivalents at beginning of period	309,771	305,619
Cash and cash equivalents at end of period	353,598	306,554
Cash and cash equivalents reported in the statement of financial position	353,598	306,554
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

Financial Statement — Statements of Changes in Stockholders' Equity

Unit: NT\$ thousand

Provided by: Mycenax Biotech Inc.
Finacial year: Yearly
Unit: NT\$ thousand

Accounting Title Ordin

Equity at end of period

Equity at beginning of period after adjustments

Capital surplus used to offset accumulated deficits

Profit (loss)

Other comprehensive income

Total comprehensive income

Share-based payments

Total increase (decrease) in equity

Equity at end of period

## 2017/09/30 Statement of Stockholders' Equity

2016/09/30 Statement of Stockholders' Equity Unit: NT\$ thousand																		
	<u>.</u>			•			·	•										
eriod	1,121,180	0	1,121,180	295,959	-73	3,541	-73,541	0	0	C	0	0	0	0	0	0	0 -87,61	1,255,987
rease) in equity	1,175	-807	368	-343,652	283	3,128	283,128	0	0	C	0	0	0	0	0	0	0	0 -60,156
nents	1,175	-807	368	13,017		0	0	0	0	C	0 0	0	0	0	0	0	0	0 13,385
ve income	0	0	0	0	-73	3,541	-73,541	0	0	C	0	C	0	0	0	0	0	0 -73,541
sive income	0	0	0	0		0	0	0	0	C	0		0	0	0	0	0	0 0
	0	0	0	0	-73	3,541	-73,541	0	0	C	0		0	0	0	0	0	0 -73,541
used to offset accumulated deficits	0	0	0	-356,669	356	6,669	356,669	0	0	C	0	0	0	0	0	0	0	0 0
g of period after adjustments used to offset accumulated deficits	1,120,005	807	1,120,812	639,611	-356	6,669	-356,669	0	0	C	0	C	0	0	0	0	0 -87,61	1,316,143
eriod	1,120,005	807	1,120,812	639,611	-356	6,669	-356,669	0	0	C	0		0	0	0	0	0 -87,61	1,316,143

								Unit: NT\$ thousand	• •					
Accounting Title	Ordinary share	Advance receipts for shar	re capital Total	share capital Ca	pital surplus Unap	ppropriated retained earnings (accumulated deficit) Total ret	tained earnings	Exchange differences on translation of foreign financial statements Gains (losses) from investments in equity instruments measured at fair value through other comprehensive incor	me Unrealized gains (losses) on available-for-sale financial assets Gains (losses) on effective portion of cash flow h	dges Gains (losses) on effective portion of hedges of net investments in foreign operations Equity related to non-current assets classified as held for sa	ale Others	Total other equity interest	Treasury shares	rotal equi
Equity at end of period	1,115,990		2,211	1,118,201	621,319	-197,695	-197,695	0	0 0	0 0	0 0	0	-87,611	1,454,21
Equity at beginning of period after adjustment	ents 1,115,990		2,211	1,118,201	621,319	-197,695	-197,695	0	0	0	0 0	0	-87,611	1,454,21
Profit (loss)	0		0	0	0	-135,912	-135,912	0	0	0	0 0	0	0	-135,91
Other comprehensive income	0		0	0	0	0	0	0	0	0	0 0	0	0	
Total comprehensive income	0		0	0	0	-135,912	-135,912	0	0	0	0 0	0	0	-135,91
Share-based payments	3,395		-1,133	2,262	12,677	0	0	0	0	0	0 0	0	0	14,939
Total increase (decrease) in equity	3,395		-1,133	2,262	12,677	-135,912	-135,912	0	0	0	0 0	0	0	-120,97
Equity at end of period	1,119,385		1,078	1,120,463	633,996	-333,607	-333,607	0	0	0	0 0	0	-87,611	1,333,24
			•	•		·			·	·				